Omeprazole

From Citizendium
Revision as of 14:07, 2 February 2023 by Pat Palmer (talk | contribs) (Text replacement - "United States" to "United States of America")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
This article is a stub and thus not approved.
Main Article
Discussion
Definition [?]
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.

Omeprazole is a pharmaceutical molecule that selectively inhibits the proton pump, specifically H+, K+-ATPase, a membrane-bound exchange pump, pumping H+in exchange for K+ across the membrane. It suppresses acidification of the fluid in the cavity (lumen) of the stomach and has medicinal value in the treatment of disorders caused or aggravated by the acidity of the fluid in the stomach (gastric) lumen.

History

Prilosec delayed release brand of omeprazole was approved for AstraZeneca by the Food and Drug Administration in the United States of America with a New Drug Application (NDA) in 1989.[1] A generic version with a AB Therapeutic Equivalence Code was approved with a Abbreviated New Drug Application (ANDA) in 2008.[2] In 4/2008, a delayed release version became an authorized generic.[3]

Pharmacology

Administration

Distribution

Metabolism

Excretion

Toxicity

Drug toxicity includes

External links

The most up-to-date information about Omeprazole and other drugs can be found at the following sites.


References

  1. Anonymous. Drugs@FDA for FDA Application No. 019810. U S Food and Drug Administration
  2. Anonymous. Drugs@FDA for FDA Application No. 075347. U S Food and Drug Administration
  3. FDA Listing of Authorized Generics as of June 27, 2011